Handelen vTv Therapeutics Inc. - VTVT CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.06 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.030779% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.013666% | ||||||||
| Tijd van overnight-tarief | 22:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | 0.88 |
| Open* | 0.89 |
| 1-Jaarlijkse Verandering* | 23.61% |
| Dagelijks bereik* | 0.85 - 0.89 |
| 52 wekelijks bereik | 0.38-1.40 |
| Weekgemiddelde volume (10 dagen) | 49.33K |
| Gemiddeld volume (3 maanden) | 1.40M |
| Marktkapitalisatie | 95.57M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 104.58M |
| Omzet | 2.02M |
| EPS | -0.31 |
| Dividend (opbrengst %) | N/A |
| Beta | -1.15 |
| Volgende inkomsten datum | Mar 27, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Feb 8, 2023 | 0.86 | -0.03 | -3.37% | 0.89 | 0.89 | 0.85 |
| Feb 7, 2023 | 0.88 | -0.02 | -2.22% | 0.90 | 0.90 | 0.88 |
| Feb 6, 2023 | 0.90 | 0.00 | 0.00% | 0.90 | 0.91 | 0.89 |
| Feb 3, 2023 | 0.91 | -0.02 | -2.15% | 0.93 | 0.95 | 0.91 |
| Feb 2, 2023 | 0.92 | 0.02 | 2.22% | 0.90 | 0.93 | 0.90 |
| Feb 1, 2023 | 0.91 | 0.02 | 2.25% | 0.89 | 0.93 | 0.87 |
| Jan 31, 2023 | 0.90 | 0.01 | 1.12% | 0.89 | 0.91 | 0.85 |
| Jan 30, 2023 | 0.89 | -0.05 | -5.32% | 0.94 | 0.94 | 0.85 |
| Jan 27, 2023 | 0.94 | -0.02 | -2.08% | 0.96 | 0.96 | 0.93 |
| Jan 26, 2023 | 0.94 | 0.00 | 0.00% | 0.94 | 0.96 | 0.88 |
| Jan 25, 2023 | 0.95 | -0.01 | -1.04% | 0.96 | 0.96 | 0.93 |
| Jan 24, 2023 | 0.96 | 0.01 | 1.05% | 0.95 | 0.97 | 0.94 |
| Jan 23, 2023 | 0.98 | -0.01 | -1.01% | 0.99 | 1.01 | 0.98 |
| Jan 20, 2023 | 0.98 | 0.02 | 2.08% | 0.96 | 1.01 | 0.95 |
| Jan 19, 2023 | 0.95 | 0.05 | 5.56% | 0.90 | 0.96 | 0.90 |
| Jan 18, 2023 | 0.89 | 0.05 | 5.95% | 0.84 | 0.90 | 0.84 |
| Jan 17, 2023 | 0.85 | 0.03 | 3.66% | 0.82 | 0.87 | 0.80 |
| Jan 13, 2023 | 0.79 | 0.02 | 2.60% | 0.77 | 0.82 | 0.77 |
| Jan 12, 2023 | 0.78 | 0.02 | 2.63% | 0.76 | 0.79 | 0.75 |
| Jan 11, 2023 | 0.78 | 0.00 | 0.00% | 0.78 | 0.80 | 0.77 |
vTv Therapeutics Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totale inkomsten | 0.634 | 0.291 | 12.434 | 2.764 | 6.414 | 4.005 |
| Inkomsten | 0.634 | 0.291 | 12.434 | 2.764 | 6.414 | 4.005 |
| Totale bedrijfskosten | 55.654 | 50.973 | 32.258 | 23.656 | 18.266 | 25.667 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 9.906 | 11.333 | 9.223 | 8.537 | 7.251 | 11.443 |
| Onderzoek & Ontwikkeling | 45.748 | 39.64 | 23.035 | 15.119 | 11.015 | 12.624 |
| Bedrijfsresultaat | -55.02 | -50.682 | -19.824 | -20.892 | -11.852 | -21.662 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.311 | -2.975 | -3.229 | -1.774 | -0.68 | -0.011 |
| Overige, Netto | -0.022 | -0.19 | -0.592 | 0.828 | -0.27 | 4.057 |
| Netto inkomen voor belastingen | -55.353 | -53.847 | -23.645 | -21.838 | -12.802 | -17.616 |
| Netto inkomen na belastingen | -55.353 | -48.8 | -23.845 | -21.938 | -12.802 | -17.731 |
| Minderheidsbelang | 39.001 | 38.503 | 15.934 | 8.894 | 4.303 | 4.744 |
| Netto inkomen voor extra. Posten | -16.352 | -10.297 | -7.911 | -13.044 | -8.499 | -12.987 |
| Netto inkomen | -16.352 | -16.144 | -7.911 | -13.044 | -8.499 | -12.987 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -16.352 | -10.297 | -8.65 | -17.913 | -8.499 | -12.987 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -16.352 | -16.144 | -8.65 | -17.913 | -8.499 | -12.987 |
| Verwaterd Netto Inkomen | -16.352 | -16.144 | -8.65 | -17.913 | -8.499 | -12.987 |
| Verwaterd Gewogen Gemiddelde Aandelen | 9.54553 | 9.69325 | 12.4492 | 30.292 | 47.1379 | 60.7326 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -1.71305 | -1.06229 | -0.69482 | -0.59134 | -0.1803 | -0.21384 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||||
| Verwaterde Genormaliseerde Winst per Aandeel | -1.71305 | -1.06229 | -0.69482 | -0.59134 | -0.1803 | -0.19671 |
| Totale buitengewone posten | -5.847 | |||||
| Total Adjustments to Net Income | -0.739 | -4.869 | 0 | |||
| Ongebruikelijke uitgaven (inkomsten) | 1.6 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0.987 | 0.009 | 3 | 0.009 | 2 |
| Inkomsten | 0.987 | 0.009 | 3 | 0.009 | 2 |
| Totale bedrijfskosten | 5.267 | 4.679 | 4.603 | 11.118 | 8.481 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 2.164 | 2.242 | 2.221 | 5.716 | 5.348 |
| Onderzoek & Ontwikkeling | 3.103 | 2.437 | 2.382 | 5.402 | 3.133 |
| Bedrijfsresultaat | -4.28 | -4.67 | -1.603 | -11.109 | -6.481 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.001 | 0 | -0.006 | -0.006 | -0.001 |
| Overige, Netto | -1.648 | 3.829 | 0.244 | 1.632 | -2.742 |
| Netto inkomen voor belastingen | -5.927 | -0.841 | -1.365 | -9.483 | -9.224 |
| Netto inkomen na belastingen | -5.942 | -0.841 | -1.465 | -9.483 | -9.424 |
| Minderheidsbelang | 1.701 | 0.233 | 0.378 | 2.432 | 2.417 |
| Netto inkomen voor extra. Posten | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Netto inkomen | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Verwaterd Netto Inkomen | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Verwaterd Gewogen Gemiddelde Aandelen | 56.4725 | 58.6151 | 61.0733 | 66.719 | 66.9428 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.0751 | -0.01037 | -0.0178 | -0.10568 | -0.10467 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.0751 | -0.01037 | -0.0178 | -0.10568 | -0.10467 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totaal vlottende activa | 52.117 | 20.362 | 3.473 | 2.838 | 7.215 | 15.621 |
| Geldmiddelen en kortetermijnbeleggingen | 51.505 | 11.758 | 1.683 | 1.777 | 5.747 | 13.415 |
| Geldmiddelen & Equivalenten | 51.505 | 11.758 | 1.683 | 1.777 | 5.747 | 13.415 |
| Totale Vorderingen, Netto | 0 | 8 | 0 | 0.005 | 0.158 | 0.057 |
| Accounts Receivable - Trade, Net | 0 | 8 | 0 | 0.005 | 0.158 | 0.057 |
| Prepaid Expenses | 0.612 | 0.442 | 0.666 | 0.806 | 0.939 | 1.914 |
| Total Assets | 54.495 | 27.917 | 8.559 | 9.266 | 14.789 | 25.474 |
| Property/Plant/Equipment, Total - Net | 0.444 | 0.283 | 0.07 | 1.004 | 0.849 | 0.68 |
| Property/Plant/Equipment, Total - Gross | 10.898 | 9.399 | 8.501 | 1.152 | 1.065 | 0.985 |
| Accumulated Depreciation, Total | -10.454 | -9.116 | -8.431 | -0.148 | -0.216 | -0.305 |
| Other Long Term Assets, Total | 1.934 | 4.792 | 2.536 | 2.944 | 0 | |
| Total Current Liabilities | 11.434 | 26.929 | 18.837 | 13.381 | 6.39 | 8.498 |
| Accounts Payable | 3.06 | 2.269 | 2.899 | 2.232 | 1.925 | 1.876 |
| Payable/Accrued | 0 | |||||
| Accrued Expenses | 8.353 | 11.632 | 4.803 | 4.946 | 4.35 | 6.331 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.021 | 8.757 | 1.752 | 0.031 | 0.031 | 0.035 |
| Total Liabilities | 145.44 | 178.964 | 91.412 | 58.289 | 94.891 | 35.214 |
| Total Long Term Debt | 11.058 | 15.316 | 6.33 | 0 | 0 | 0 |
| Long Term Debt | 11.058 | 15.316 | 6.33 | 0 | ||
| Minority Interest | 122.515 | 131.44 | 62.482 | 40.183 | 83.895 | 24.962 |
| Other Liabilities, Total | 0.433 | 5.279 | 3.763 | 4.725 | 4.606 | 1.754 |
| Total Equity | -90.945 | -151.047 | -82.853 | -49.023 | -80.102 | -9.74 |
| Common Stock | 0.329 | 0.329 | 0.435 | 0.641 | 0.773 | 0.901 |
| Additional Paid-In Capital | 124.212 | 127.682 | 150.595 | 183.858 | 209.161 | 238.193 |
| Retained Earnings (Accumulated Deficit) | -215.486 | -279.058 | -233.883 | -233.522 | -290.036 | -248.834 |
| Total Liabilities & Shareholders’ Equity | 54.495 | 27.917 | 8.559 | 9.266 | 14.789 | 25.474 |
| Total Common Shares Outstanding | 32.8125 | 32.8125 | 43.4413 | 64.0127 | 77.1449 | 90.0366 |
| Other Current Assets, Total | 0.162 | 1.124 | 0.25 | 0.371 | 0.235 | |
| Long Term Investments | 2.48 | 2.48 | 2.48 | 6.725 | 9.173 | |
| Current Port. of LT Debt/Capital Leases | 4.271 | 9.383 | 6.172 | 0.084 | 0.256 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 9.221 | 11.272 | 22.171 | 15.621 | 13.612 |
| Geldmiddelen en kortetermijnbeleggingen | 8.449 | 10.835 | 19.566 | 13.415 | 12.138 |
| Geldmiddelen & Equivalenten | 8.449 | 10.835 | 19.566 | 13.415 | 12.138 |
| Totale Vorderingen, Netto | 0.002 | 0 | 0.928 | 0.057 | 0.057 |
| Accounts Receivable - Trade, Net | 0.002 | 0 | 0.928 | 0.057 | 0.057 |
| Prepaid Expenses | 0.71 | 0.313 | 1.574 | 2.049 | 1.387 |
| Other Current Assets, Total | 0.06 | 0.124 | 0.103 | 0.1 | 0.03 |
| Total Assets | 16.754 | 21.66 | 31.434 | 25.474 | 20.185 |
| Property/Plant/Equipment, Total - Net | 0.808 | 0.766 | 0.724 | 0.68 | 0.634 |
| Long Term Investments | 6.725 | 9.622 | 8.539 | 9.173 | 5.939 |
| Total Current Liabilities | 5.162 | 5.059 | 5.51 | 8.498 | 12.7 |
| Payable/Accrued | 4.965 | 4.855 | 4.663 | 8.023 | 12.474 |
| Accrued Expenses | 0.162 | 0.169 | 0.176 | 0.184 | 0.191 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 0.636 | 0.256 | 0 |
| Other Current Liabilities, Total | 0.035 | 0.035 | 0.035 | 0.035 | 0.035 |
| Total Liabilities | 73.029 | 69.483 | 52.979 | 35.214 | 28.278 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 62.647 | 60.19 | 44.61 | 24.962 | 14.367 |
| Other Liabilities, Total | 5.22 | 4.234 | 2.859 | 1.754 | 1.211 |
| Total Equity | -56.275 | -47.823 | -21.545 | -9.74 | -8.093 |
| Common Stock | 0.808 | 0.834 | 0.897 | 0.901 | 0.901 |
| Additional Paid-In Capital | 217.647 | 224.457 | 236.557 | 238.193 | 238.669 |
| Retained Earnings (Accumulated Deficit) | -274.73 | -273.114 | -258.999 | -248.834 | -247.663 |
| Total Liabilities & Shareholders’ Equity | 16.754 | 21.66 | 31.434 | 25.474 | 20.185 |
| Total Common Shares Outstanding | 80.6658 | 83.2878 | 89.565 | 90.0366 | 90.0366 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -55.353 | -54.647 | -23.845 | -21.938 | -12.802 | -17.731 |
| Geldmiddelen uit Operationele Activiteiten | -48.209 | -44.56 | -26.856 | -23.018 | -18 | -19.308 |
| Geldmiddelen uit Operationele Activiteiten | 0.265 | 0.197 | 0.218 | 0.039 | 0.094 | 0.089 |
| Niet-Geldelijke Posten | 2.793 | 4.853 | 4.316 | 0.935 | -2.586 | -1.701 |
| Contant Betaalde Rente | 0.242 | 2.064 | 2.276 | 1.295 | 0.623 | 0.011 |
| Veranderingen in het Operationeel Kapitaal | 4.086 | 5.037 | -7.545 | -2.054 | -2.706 | 0.035 |
| Geldmiddelen uit Investeringsactiviteiten | -0.083 | -0.025 | 0.007 | 0.242 | 0 | 0 |
| Kapitaaluitgaven | -0.087 | -0.057 | -0.005 | -0.07 | 0 | 0 |
| Overige Cash Flow investeringsposten, Totaal | 0.004 | 0.032 | 0.012 | 0.312 | 0 | 0 |
| Geldmiddelen uit Financieringsactiviteiten | 11.794 | 7.5 | 16.612 | 22.87 | 19.47 | 26.976 |
| Financiering van Cash Flow Posten | -0.673 | 0 | 0 | |||
| Uitgifte (Aflossing) van aandelen, netto | 0 | 0 | 21.5 | 32.943 | 24.426 | 26.804 |
| Uitgifte (Aflossing) van Schulden, Netto | 12.467 | 7.5 | -4.888 | -10.073 | -4.956 | 0.172 |
| Nettowijziging in Geldmiddelen | -36.498 | -37.085 | -10.237 | 0.094 | 1.47 | 7.668 |
| Cash Taxes Paid | 1 | 0.1 | 0 | 0.115 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -5.942 | -6.783 | -8.248 | -17.731 | -9.424 |
| Cash From Operating Activities | -5.299 | -9.297 | -12.891 | -19.308 | -1.021 |
| Cash From Operating Activities | 0.023 | 0.045 | 0.067 | 0.089 | 0.023 |
| Non-Cash Items | 2.084 | -1.292 | -1.063 | -1.701 | 3.218 |
| Changes in Working Capital | -1.464 | -1.267 | -3.647 | 0.035 | 5.162 |
| Cash From Financing Activities | 8.001 | 14.385 | 26.71 | 26.976 | -0.256 |
| Issuance (Retirement) of Stock, Net | 8.085 | 14.469 | 26.158 | 26.804 | 0 |
| Issuance (Retirement) of Debt, Net | -0.084 | -0.084 | 0.552 | 0.172 | -0.256 |
| Net Change in Cash | 2.702 | 5.088 | 13.819 | 7.668 | -1.277 |
| Cash From Investing Activities | 0 | ||||
| Capital Expenditures | 0 | ||||
| Other Investing Cash Flow Items, Total | 0 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| MacAndrews & Forbes Holdings, Inc. | Holding Company | 44.9246 | 36606212 | 87000 | 2022-05-31 | LOW |
| G42 Investments AI Holdings RSC, Ltd. | Corporation | 12.7465 | 10386274 | 10386274 | 2022-05-31 | LOW |
| Medpace Investors, L.L.C. | Corporation | 6.6241 | 5397529 | 5397529 | 2022-08-16 | LOW |
| Samsara BioCapital, LLC | Venture Capital | 2.0072 | 1635509 | 0 | 2022-09-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.1523 | 938970 | 0 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3559 | 290000 | -76618 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1654 | 134745 | -71400 | 2022-09-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.0949 | 77339 | -61344 | 2022-09-30 | HIGH |
| Fry (John Anthony) | Individual Investor | 0.0749 | 61000 | 61000 | 2022-11-29 | LOW |
| Nelson (Rich S) | Individual Investor | 0.0736 | 60000 | 0 | 2022-04-04 | |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.0661 | 53845 | -287 | 2022-09-30 | LOW |
| Virtu Americas LLC | Research Firm | 0.0539 | 43954 | 5395 | 2022-09-30 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0498 | 40577 | 0 | 2022-09-30 | LOW |
| PGIM Quantitative Solutions LLC | Investment Advisor | 0.0491 | 40000 | 0 | 2022-09-30 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.041 | 33442 | 0 | 2022-09-30 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.0405 | 33012 | -4256 | 2022-09-30 | HIGH |
| Two Sigma Investments, LP | Hedge Fund | 0.0397 | 32385 | 14590 | 2022-09-30 | HIGH |
| Simon Quick Advisors, LLC | Investment Advisor | 0.0368 | 30000 | 0 | 2022-12-31 | MED |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.0332 | 27018 | 27018 | 2022-09-30 | LOW |
| Kozlov (Hersh) | Individual Investor | 0.0307 | 25000 | 0 | 2022-04-04 |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group +500000+
Handelaren
93000+
Actieve klanten per maand
$57000000+
Maandelijks beleggingsvolume
$31000000+
Probeer het nu Opgenomen per maand
Handelscalculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Handelscommissie
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Hefboom
20:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
vTv Therapeutics Inc. Company profile
Over vTv Therapeutics Inc.
vTv Therapeutics Inc. is een farmaceutisch bedrijf in klinische ontwikkeling dat zich bezighoudt met het onderzoek naar en de ontwikkeling van oraal toegediende kleine molecule kandidaat-geneesmiddelen. Het ontwikkelt een programma voor de behandeling van type I diabetes TTP399 en voor psoriasis HPP737. TTP399 is een oraal toegediende, kleine molecule, lever-selectieve glucokinase-activator (GKA) in ontwikkeling potentieel oraal anti-diabeticum voor de behandeling van type I-diabetes. TTP399 voltooide de SimpliciT-I studie, een Fase II studie bij patiënten met type I diabetes als een aanvulling op insulinetherapie. De Vennootschap voert ook een Fase I studie uit met meerdere oplopende dosissen HPP737, een oraal toegediende fosfodiësterase type IV remmer, om de farmacokinetiek, farmacodynamiek, veiligheid en verdraagbaarheid van HPP737 in gezonde vrijwilligers te beoordelen als onderdeel van haar psoriasisprogramma. TTP273 is een oraal toegediende, kleine molecule, glucagon-like peptide I (GLP-1) receptor agonist die wordt geëvalueerd voor de behandeling van type II diabetes mellitus.
| Industry: | Bio Therapeutic Drugs |
3980 Premier Dr
Suite 310
HIGH POINT
NORTH CAROLINA 27265
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen